BAFF-targeting therapy, a promising strategy for treating autoimmune diseases

European Journal of Pharmacology

Volumn 597, Issue 1-3, 2008, Pages 1-5

  Sun, Jian ^a   Lin, Zhou ^b   Feng, Jiannan ^b   Li, Yan ^b   Shen, Beifen ^b  

^a TIANJIN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Autoimmune disease; BAFF; Rituximab; Therapy

Indexed keywords

ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELL SURVIVAL; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 53449084380     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.08.027     Document Type: Review

References (53)

1. Allman D., Srivastava B., and Lindsley R.C. Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells. Immunol. Rev. 197 (2004) 147-160
2. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317
3. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., Lappin P.B., Riccobene T., Abramian D., Sekut L., Sturm B., Poortman C., Minter R.R., Dobson C.L., Williams E., Carmen S., Smith R., Roschke V., Hilbert D.M., Vaughan T.J., and Albert V.R. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48 (2003) 3253-3265
4. Bossen C., and Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18 (2006) 263-275
5. Cambridge G., Isenberg D.A., Edwards J.C., Leandro M.J., Migone T.S., Teodorescu M., and Stohl W. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67 (2008) 1011-1016
6. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44 (2001) 1313-1319
7. Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3 (2002) 958-965
8. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., Hessey E.W., Shaw T., Totoritis M.C., and REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54 (2006) 2793-2806
9. Craxton A., Magaletti D., Ryan E.J., and Clark E.A. Macrophage- and dendritic cell-dependent regulation of human B cell proliferation requires the TNF family ligand BAFF. Blood 101 (2003) 4464-4471
10. Craxton A., Draves K.E., Gruppi A., and Clark E.A. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J. Exp. Med. 202 (2005) 1363-1374
11. Crowley J.E., Treml L.S., Stadanlick J.E., Carpenter E., and Cancro M.P. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin. Immunol. 17 (2005) 193-199
12. Dall Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., Kalunian K., Dhar P., Vincent E., Pena-Rossi C., and Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56 (2007) 4142-4150
13. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 40 (2001) 205-211
14. Edwards J.C., Cambridge G., and Leandro M.J. B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. 20 (2006) 915-928
15. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F., Li N.F., Agarwal S., Hessey E.W., Shaw T.M., and DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54 (2006) 1390-1400
16. Enders A., Bouillet P., Puthalakath H., Xu Y., Tarlinton D.M., and Strasser A. Loss of the proapoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J. Exp. Med. 198 (2003) 1119-1126
17. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., and Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109 (2002) 59-68
18. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., Smyth M.J., Mackay C.R., and Mackay F. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204 (2007) 1959-1971
19. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., Moore M., Littau A., Grossman A., Haugen H., Foley K., Blumberg H., Harrison K., Kindsvogel W., and Clegg C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
20. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., Rixon M., Schou O., Foley K.P., Haugen H., McMillen S., Waggie K., Schreckhise R.W., Shoemaker K., Vu T., Moore M., Grossman A., and Clegg C.H. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15 (2001) 289-302
21. Hatzoglou A., Roussel J., Bourgeade M.F., Rogier E., Madry C., Inoue J., Devergne O., and Tsapis A. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165 (2000) 1322-1330
22. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H., and HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
23. Katsenelson N., Kanswal S., Puig M., Mostowski H., Verthelyi D., and Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 37 (2007) 1785-1795
24. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., Hawkins N., Kelley M., Chang D., Van G., Ross L., Delaney J., Wang L., Lacey D., Boyle W.J., and Hsu H. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3370-3375
25. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54 (2006) 613-620
26. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2673-2677
27. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., and Cyster J.G. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20 (2004) 441-453
28. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., and Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190 (1999) 1697-1710
29. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Ann. Rev. Immunol. 24 (2006) 467-496
30. Martin F., and Chan A.C. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20 (2004) 517-527
31. Mecklenbrouker I., Kalled S.L., Leitges M., Mackay F., and Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 431 (2004) 456-461
32. Meyer-Bahlburg A., Andrews S.F., Yu K.O., Porchelli S.A., and Rawlings D.J. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J. Exp. Med. 205 (2008) 155-168
33. Meyer-Bahlburg A., and Rawlings D.J. B cell autonomous TLR signaling and autoimmunity. Autoimmunity 7 (2008) 313-316
34. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., Soppet D., Charters M., Gentz R., Parmelee D., Li Y., Galperina O., Giri J., Roschke V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., Ruben S.M., Olsen H.S., Fikes J., and Hilbert D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285 (1999) 260-263
35. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., Sosnovtseva S., Carrell J.A., Feng P., Giri J.G., and Hilbert D.M. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97 (2001) 198-204
36. Ramanujam M., Wang X., Huang W., Schiffer L., Grimaldi C., Akkerman A., Diamond B., Madaio M.P., and Davidson A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173 (2004) 3524-3534
37. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., Frew E., and Scott M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293 (2001) 2111-2114
38. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R.H., Browning J.L., and Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189 (1999) 1747-1756
39. Shu H.B., and Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9156-9161
40. Shu H.B., Hu W.H., and Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 65 (1999) 680-683
41. Sun J., Feng J., Li Y., and Shen F. A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS. Biochem. Biophys. Res. Commun. 346 (2006) 1158-1162
42. Sutherland A.P., Mackay F., and Mackay C.R. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol. Ther. 112 (2006) 774-786
43. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., Rischmueller M., Nasonov E., Shmidt E., Emery P., and Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58 (2008) 61-72
44. Thanos C.D., DeLano W.L., and Wells J.A. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15422-15427
45. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., and Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
46. Thomas M.D., Kremer C.S., Ravichandran K.S., Rajewsky K., and Bender T.P. c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 23 (2005) 275-286
47. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., Hession C., Schneider P., Sizing I.D., Mullen C., Strauch K., Zafari M., Benjamin C.D., Tschopp J., Browning J.L., and Ambrose C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 (2001) 2108-2111
48. Tsokos G.C. B cells, be gone-B-cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2546-2548
49. Treml L.S., Carlesso G., Hoek K.L., Stadanlick J.E., Kambayashi T., Bram R.J., Cancro M.P., and Khan W.N. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 178 (2007) 7531-7539
50. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., and Malmström V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 8 (2006) R167
51. Wang H., Marsters S.A., Baker T., Chan B., Lee W.P., Fu L., Tumas D., Yan M., Dixit V.M., Ashkenazi A., and Grewal I.S. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol. 2 (2001) 632-637
52. Xia X.Z., Treanor J., Senaldi G., Khare S.D., Boone T., Kelley M., Theill L.E., Colombero A., Solovyev I., Lee F., McCabe S., Elliott R., Miner K., Hawkins N., Guo J., Stolina M., Yu G., Wang J., Delaney J., Meng S.Y., Boyle W.J., and Hsu H. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. 192 (2000) 137-143
53. Xu L.G., and Shu H.B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J. Immunol. 169 (2002) 6883-6889